Cargando…

DIPG-04. THERAPEUTIC STRATEGY FOR DIFFUSE MIDLINE GLIOMAS. A SINGLE CENTER EXPERIENCE

INTRODUCTION: Diffuse midline gliomas have unfavorable prognoses due to the difficulty of surgery and chemo-radiation resistances. The purpose of this study is to overview our surgical experiences and prognoses of this challenging neoplasm. MATERIALS AND METHODS: Five patients of diffuse midline gli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamanaka, Takumi, Takahashi, Yoshinobu, Morisako, Tamaki, Nagai, Toshiki, Tanigawa, Seisuke, Umebayashi, Daisuke, Takeuchi, Hayato, Tatsuzawa, Kazunori, Miyachi, Mitsuru, Yagyu, Shigeki, Iehara, Tomoko, Hosoi, Hajime, Hashimoto, Naoya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Diffuse Midline Glioma/DIPG
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715733/ http://dx.doi.org/10.1093/neuonc/noaa222.056

Ejemplares similares

DIPG-39. New preclinical models for Diffuse Midline Glioma
por: Klenner, Marbod, et al.
Publicado: (2022)

DIPG-06. Uncovering the FACTs in Diffuse Midline Glioma (DMG)
por: Holliday, Holly, et al.
Publicado: (2022)

DIPG-17. BIOPSY-PROVEN DIFFUSE MIDLINE GLIOMA IN ADOLESCENTS AND YOUNG ADULTS
por: Tanaka, Shota, et al.
Publicado: (2020)

DIPG-31. MOLECULAR MECHANISMS AND FUNCTIONAL IMPACT OF ABERRANT SPLICING IN DIFFUSE MIDLINE GLIOMAS
por: Naqvi, Ammar, et al.
Publicado: (2020)

DIPG-42. Diffuse midline gliomas, H3K27-altered as an interdisciplinary challenge
por: Kammler, Gertrud, et al.
Publicado: (2022)

DIPG-61. Preclinical efficacy of combined radiotherapy with venetoclax treatment in targeting diffuse midline gliomas
por: Madhavan, Krishna, et al.
Publicado: (2022)

DIPG-76. HISTONE H3 PHOSPHORYLATION IN H3K27M MIDLINE GLIOMAS
por: Zhang, Liang, et al.
Publicado: (2020)

DIPG-47. HISTONE MUTATIONS ENHANCE RAS MEDIATED ERK5 GROWTH SIGNALING IN DIFFUSE MIDLINE GLIOMAS
por: Stanton, Ann-Catherine, et al.
Publicado: (2020)

DIPG-44. H3K27-altered diffuse midline gliomas with secondary driver molecular alterations
por: Gestrich, Catherine, et al.
Publicado: (2022)

DIPG-74. RE-IRRADIATION OF DIPG: DATA FROM THE INTERNATIONAL DIPG REGISTRY
por: Lafay-Cousin, Lucie, et al.
Publicado: (2020)

DIPG-50. Bioinformatic evaluation of genes involved in sphingomyelin biosynthesis in Diffuse Midline Glioma H3K27 altered/DIPG: dysregulation of sphingosine 1-phosphate (SP1)
por: Humphreys, Aimee, et al.
Publicado: (2022)

DIPG-37. PREDICTING OUTCOME IN CHILDHOOD DIFFUSE MIDLINE GLIOMAS USING MAGNETIC RESONANCE IMAGING BASED TEXTURE ANALYSIS
por: Szychot, Elwira, et al.
Publicado: (2020)

DIPG-64. INTERNATIONAL PRECLINICAL DRUG DISCOVERY AND BIOMARKER PROGRAM INFORMING AN ADOPTIVE COMBINATORIAL TRIAL FOR DIFFUSE MIDLINE GLIOMAS
por: Przystal*, Justyna M, et al.
Publicado: (2020)

DIPG-48. MRI volumetric and machine learning based analyses predict survival outcome in pediatric diffuse midline glioma
por: Bonner, Erin R, et al.
Publicado: (2022)

DIPG-40. Combined pharmacological and genetic screening to identify dependencies and combinations in ACVR1-mutant diffuse midline glioma
por: Rogers, Rebecca, et al.
Publicado: (2022)

DIPG-09. Diffuse Midline Glioma-Adaptive Combinatory Trial (DMG-ACT): A biology-driven platform trial in pediatric and young adult patients with diffuse midline glioma
por: Franson, Andrea, et al.
Publicado: (2022)

DIPG-16. Evaluation of myeloid component of DIPG microenvironment
por: Mishra, Deepak, et al.
Publicado: (2022)

DIPG-03. Therapeutic targeting of purine biosynthesis in DIPG
por: Mersich, Ian, et al.
Publicado: (2022)

DIPG-34. SUPER ELONGATION COMPLEX AS A TARGETABLE DEPENDENCY IN H3K27M+ DIFFUSE MIDLINE GLIOMA
por: Dahl, Nathan, et al.
Publicado: (2020)

DIPG-19. TARGETING ATM MUTATION IN METASTATIC DIFFUSE MIDLINE GLIOMA – A CASE OF SUSTAINED RESPONSE USING PARP INHIBITOR
por: Tsui, Karen, et al.
Publicado: (2020)

DIPG-45. Radiation induces a robust interferon response in Diffuse Midline Glioma (DMG), improving the potential for combination immunotherapy
por: Minns, Hanna E, et al.
Publicado: (2022)

DIPG-56. Development and application of a novel antibody against CD99 as a therapeutic strategy in Diffuse Midline Glioma
por: Venkataraman, Sujatha, et al.
Publicado: (2022)

DIPG-58. HISTONE H3 WILD-TYPE DIPG/DMG OVEREXPRESSING EZHIP EXTEND THE SPECTRUM OF DIFFUSE MIDLINE GLIOMAS WITH PRC2 INHIBITION BEYOND H3-K27M MUTATION
por: Castel, David, et al.
Publicado: (2020)

DIPG-46. NON-DIPG PATIENTS ENROLLED IN THE INTERNATIONAL DIPG REGISTRY: HISTOPATHOLOGIC EVALUATION OF CENTRAL NEURO-IMAGING REVIEW
por: Lazow, Margot A, et al.
Publicado: (2020)

DIPG-78. REVERTANCE OF THE H3K27M MUTATION RESCUES CHROMATIN MARKS NECESSARY FOR ONCOGENESIS IN DIFFUSE MIDLINE GLIOMA
por: Nesvick, Cody, et al.
Publicado: (2020)

DIPG-20. DETERMINATION AND MANAGEMENT OF HYDROCEPHALUS IN PATIENTS WITH DIPG, AN INSTITUTIONAL EXPERIENCE
por: Fonseca, Adriana, et al.
Publicado: (2020)

DIPG-70. DISORDERED DNA METHYLATION IN DIPG UNDERLIES PHENOTYPIC PLASTICITY
por: Koldobskiy, Michael, et al.
Publicado: (2020)

DIPG-59. UPREGULATION OF PRENATAL PONTINE ID1 SIGNALING IN DIPG
por: Harris, Micah K, et al.
Publicado: (2020)

DIPG-57. TRANSCRIPTOMIC AND PROTEOMIC ANALYSES OF DIPG RESPONSE TO ONC201
por: Sridharan, Sreepradha, et al.
Publicado: (2020)

DIPG-12. TARGETING EPIGENETIC MODIFIERS TO INDUCE IMMUNE SIGNALING IN DIPG
por: Tetens, Ashley, et al.
Publicado: (2020)

DIPG-52. Activators of the integrated stress response synergize to kill DIPG
por: Novak, Orlandi, et al.
Publicado: (2022)

DIPG-23. SINGLE CASE REPORT OF LOW DOSE RADIOTHERAPY AND CHEMOTHERAPY IN THE TREATMENT OF DIPG
por: Tseng, Chen Kan, et al.
Publicado: (2020)

DIPG-40. TARGETING MASTER REGULATOR DEPENDENCIES IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Pavisic, Jovana, et al.
Publicado: (2020)

DIPG-75. PRECISION MEDICINE FOR PAEDIATRIC HIGH-GRADE DIFFUSE MIDLINE GLIOMAS - RESULTS FROM THE ZERO CHILDHOOD CANCER COMPREHENSIVE PRECISION MEDICINE PROGRAM
por: Khuong-Quang, Dong-Anh, et al.
Publicado: (2020)

DIPG-47. TSO500ctDNA sequencing reveals oncogenic mutations and copy number variations in the liquid biome of children with diffuse midline glioma
por: Bonner, Erin R, et al.
Publicado: (2022)

DIPG-38. Significant tumor regression of H3K27M-mutated diffuse midline glioma of the brainstem with panobinostat: a case report.
por: Partap, Sonia, et al.
Publicado: (2022)

DIPG-37. Exploring the role of the epigenetic factor H2A.Z acetylation in DIPG
por: Sanguino, Yolanda Colino, et al.
Publicado: (2022)

DIPG-56. EXPLORATION OF TUMOR/STROMA INTERACTIONS IN DIPG XENOGRAFT BY SPECIES-SPECIFIC RNA-SEQ DECONVOLUTION INDICATES A ROLE OF MICROGLIA CELL IN DIPG DEVELOPMENT
por: Merlevede, Jane, et al.
Publicado: (2020)

DIPG-28. REPEATED LOW DOSE RT FOR PEDIATRIC DIPG – LESS DISEASE BURDEN WITH COMPARABLE OUTCOMES
por: Wu, Yao Yu, et al.
Publicado: (2020)

DIPG-32. AKT SIGNALING DRIVES RESISTANCE TO ONC201 IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Jackson, Evangeline R, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_meq5jdifdpp37kvs1dnjev7c7c